MCID: PRM003
MIFTS: 44

Premature Ejaculation

Categories: Mental diseases

Aliases & Classifications for Premature Ejaculation

MalaCards integrated aliases for Premature Ejaculation:

Name: Premature Ejaculation 12 44 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:13709
ICD9CM 34 302.75
MeSH 44 D061686
NCIt 50 C94349
SNOMED-CT 67 123302009
ICD10 32 F52.4
UMLS 70 C0033038

Summaries for Premature Ejaculation

MalaCards based summary : Premature Ejaculation is related to sexual disorder and prostatic hyperplasia, benign. An important gene associated with Premature Ejaculation is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are cAMP signaling pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Sodium citrate and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include cervix, prostate and brain, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 73 Premature ejaculation (PE) occurs when a man experiences orgasm and expels semen within a few moments of... more...

Related Diseases for Premature Ejaculation

Diseases related to Premature Ejaculation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 sexual disorder 30.7 SLC6A4 PDE5A OXT HTR2C HTR1A AR
2 prostatic hyperplasia, benign 30.2 PDE5A AR
3 depression 30.2 SLC6A4 HTR2C HTR1A
4 withdrawal disorder 30.1 SLC6A3 HTR1A AR
5 hypogonadism 30.0 PDE5A LEP AR
6 serotonin syndrome 30.0 SLC6A4 OXT HTR1A
7 irritable bowel syndrome 29.8 SLC6A4 HTR1A COMT
8 prostatic hypertrophy 29.7 CYP19A1 AR
9 hypogonadotropic hypogonadism 29.5 LEP CYP19A1 AR
10 substance abuse 29.5 SLC6A4 SLC6A3 HTR1B HTR1A COMT
11 social phobia 29.5 SLC6A4 OXT LOC110806262 HTR1A COMT
12 alexithymia 29.3 SLC6A4 OXT LOC110806262 HTR1A COMT
13 psychosexual disorder 29.3 SLC6A4 PDE5A OXT HTR2C HTR1B HTR1A
14 anxiety 29.3 SLC6A4 SLC6A3 OXT HTR2C HTR1B HTR1A
15 impulse control disorder 29.1 SLC6A4 SLC6A3 HTR2C HTR1B HTR1A COMT
16 alcohol use disorder 29.1 SLC6A4 SLC6A3 HTR2C HTR1B HTR1A COMT
17 panic disorder 29.0 SLC6A4 SLC6A3 HTR2C HTR1B HTR1A COMT
18 mood disorder 29.0 SLC6A4 SLC6A3 HTR2C HTR1B HTR1A COMT
19 alcohol dependence 28.7 SLC6A4 SLC6A3 LEP HTR2C HTR1B HTR1A
20 mental depression 28.7 SLC6A4 SLC6A3 OXT HTR2C HTR1B HTR1A
21 attention deficit-hyperactivity disorder 28.7 SLC6A4 SLC6A3 OXT HTR2C HTR1B HTR1A
22 impotence 11.0
23 prostatitis 10.7
24 hyperthyroidism 10.4
25 body mass index quantitative trait locus 1 10.3
26 varicocele 10.3
27 pik3ca-related overgrowth syndrome 10.3
28 alcoholic psychosis 10.3 SLC6A4 SLC6A3
29 allergic disease 10.3
30 retrograde amnesia 10.3 SLC6A4 HTR1A
31 trigeminal neuralgia 10.2 SLC6A4 LOC110806262
32 animal phobia 10.2 SLC6A4 OXT
33 diamond-blackfan anemia 5 10.2 SLC6A4 HTR1A
34 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
35 constipation 10.2
36 paraphilia disorder 10.2 SLC6A4 OXT
37 dissociative disorder 10.2 SLC6A4 OXT
38 motion sickness 10.2 HTR1B HTR1A
39 body dysmorphic disorder 10.2 SLC6A4 OXT
40 melancholia 10.2 SLC6A4 LOC110806262 HTR1A
41 microscopic colitis 10.2 SLC6A4 LOC110806262
42 syncope 10.2
43 microphthalmia, syndromic 13 10.1 SLC6A4 AR
44 delusional disorder 10.1 SLC6A3 HTR2C HTR1A
45 chronic pulmonary heart disease 10.1 SLC6A4 PDE5A
46 amphetamine abuse 10.1 SLC6A4 SLC6A3 HTR1B
47 lingual-facial-buccal dyskinesia 10.1 SLC6A3 HTR2C HTR1A
48 obsessive-compulsive personality disorder 10.1 SLC6A4 COMT
49 fetal macrosomia 10.1 OXT LEP
50 metachromatic leukodystrophy 10.1 SLC6A4 SLC6A3 HTR1A

Graphical network of the top 20 diseases related to Premature Ejaculation:



Diseases related to Premature Ejaculation

Symptoms & Phenotypes for Premature Ejaculation

MGI Mouse Phenotypes related to Premature Ejaculation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 AR COMT CYP19A1 HTR1A HTR1B HTR2C
2 cardiovascular system MP:0005385 10.01 AR COMT CYP19A1 HTR1A HTR1B LEP
3 adipose tissue MP:0005375 10 AR CYP19A1 HTR1A HTR1B HTR2C LEP
4 endocrine/exocrine gland MP:0005379 9.97 AR COMT CYP19A1 HTR1B LEP OXT
5 integument MP:0010771 9.87 AR CYP19A1 HTR2C LEP OXT SLC6A3
6 nervous system MP:0003631 9.85 AR COMT CYP19A1 HTR1A HTR2C LEP
7 muscle MP:0005369 9.8 AR CYP19A1 HTR1B HTR2C LEP SLC6A3
8 pigmentation MP:0001186 9.26 AR CYP19A1 HTR2C LEP
9 reproductive system MP:0005389 9.17 AR COMT CYP19A1 HTR1B LEP OXT

Drugs & Therapeutics for Premature Ejaculation

Drugs for Premature Ejaculation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
4 Sildenafil Citrate Phase 4 171599-83-0
5 Citrate Phase 4
6 Phosphodiesterase 5 Inhibitors Phase 4
7 Phosphodiesterase Inhibitors Phase 4
8 Vasodilator Agents Phase 4
9
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
10
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
11
Prilocaine Approved Phase 2, Phase 3 721-50-6 4906
12
Norflurane Approved, Experimental Phase 2, Phase 3 811-97-2
13
Clomipramine Approved, Investigational, Vet_approved Phase 3 303-49-1 2801
14
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
16
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
17
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
18
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
21
Cobalamin Experimental Phase 3 13408-78-1 6857388
22 Adrenergic Antagonists Phase 3
23 Adrenergic alpha-1 Receptor Antagonists Phase 3
24 Adrenergic alpha-Antagonists Phase 3
25 Adrenergic Agents Phase 3
26 Neurotransmitter Agents Phase 3
27 Psychotropic Drugs Phase 3
28 Serotonin Uptake Inhibitors Phase 3
29 Antidepressive Agents Phase 3
30 Adjuvants, Immunologic Phase 3
31 Viscosupplements Phase 3
32 Protective Agents Phase 3
33 Immunologic Factors Phase 3
34 Lidocaine, Prilocaine Drug Combination Phase 2, Phase 3
35 Antidepressive Agents, Tricyclic Phase 3
36 Vardenafil Dihydrochloride Phase 3
37 Hematinics Phase 3
38 Trace Elements Phase 3
39 Nutrients Phase 3
40 Vitamin B Complex Phase 3
41 Vitamin B12 Phase 3
42 Micronutrients Phase 3
43 Folate Phase 3
44 Vitamin B 12 Phase 3
45 Vitamins Phase 3
46 Vitamin B9 Phase 3
47 Anesthetics Phase 3
48 Anesthetics, Local Phase 3
49 Sodium Channel Blockers Phase 3
50 Anti-Arrhythmia Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study) Completed NCT02939495 Phase 4 Dapoxetine/Sildenafil 30/50 mg film coated tablet
2 The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction Active, not recruiting NCT03177746 Phase 4 Dapoxetine/Tadalafil 30/20 mg film coated tablet
3 Effect of Tamsulosin on Premature Ejaculation Compared With Paroxetine Hydrochloride Unknown status NCT03879746 Phase 3 Tamsulosin;Paroxetine Hydrochloride
4 A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation Unknown status NCT02241460 Phase 3 Placebo;Promescent Lidocaine Spray
5 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Unknown status NCT03629769 Phase 3 Proxelan
6 A Parallel Randomized Double Blind Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation Completed NCT01024491 Phase 3 paroxetine;paroxetine;placebo
7 Glans Penis Augmentation by Hyaluronic Acid for Treatment of Premature Ejaculation: Randomized Controlled Cross-over Trial Completed NCT03459833 Phase 3 Hyaluronic Acid
8 A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation Completed NCT00210704 Phase 3 Dapoxetine
9 A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As-Needed Dosing With Dapoxetine in the Treatment of Premature Ejaculation Completed NCT00210613 Phase 3 Dapoxetine
10 A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study Of The Efficacy And Safety Of Dapoxetine In The Treatment Of Subjects With Premature Ejaculation Completed NCT00229073 Phase 3 dapoxetine
11 A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation Completed NCT00211107 Phase 3 Dapoxetine
12 A Placebo-Controlled, Double-blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation Completed NCT00211094 Phase 3 Dapoxetine
13 The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy Completed NCT01063881 Phase 3 Dapoxetine
14 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor Completed NCT01063855 Phase 3 Placebo;Dapoxetine;PDE5I (phosphodiesterase-5 inhibitor)
15 A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients With Premature Ejaculation Completed NCT01439984 Phase 3 Clomipramine
16 A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE) Completed NCT00556478 Phase 2, Phase 3 PSD502, contains a mixture of lidocaine and prilocaine;Placebo
17 A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation Completed NCT00143117 Phase 2, Phase 3 UK-390,957
18 A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation Completed NCT00219583 Phase 2, Phase 3 UK-390,957
19 Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation: A Randomized Placebo-controlled Clinical Trial Completed NCT04085354 Phase 3 Multi-Vitamin Tablets;Dapoxetine;Dapoxetine and folic acid.;Dapoxetine and vitamin B12
20 A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation Completed NCT00219635 Phase 2, Phase 3 UK-390,957
21 A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation Completed NCT00219609 Phase 2, Phase 3 UK-390,957
22 Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone. Recruiting NCT04703127 Phase 3 Tadalafil and Combined Dapoxietine;Dapoxietine and Combined Lidocaine 5% Spray
23 Multicenter Study of the Efficacy and Safety of Dapoxetine Combined With Tadalafil in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Not yet recruiting NCT04361305 Phase 3 Dapoxetine;Tadalafil;Tadalafil
24 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation Terminated NCT00983736 Phase 3 Tramadol Hydrochloride;Placebo
25 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation Terminated NCT00983151 Phase 3 Tramadol Hydrochloride & Placebo
26 Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Unknown status NCT02581826 Phase 2 Silodosin;Placebo
27 A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation Unknown status NCT02571101 Phase 2 CDFR0812-15/25mg;CDFR0812-15/50mg;Condencia;CDFR0812-Placebo;Condencia-Placebo
28 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 After Oral Administration in Male Patients With Premature Ejaculation Unknown status NCT01798667 Phase 2 DA-8031;Placebo
29 A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men With Premature Ejaculation Completed NCT01021553 Phase 2 GSK557296;GSK557296;placebo
30 A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped Clinical Study to Evaluate the Tolerability and to Determine the Adequate Dosage of PED-1 and PED-2 in Male Patients With Premature Ejaculation Completed NCT01203202 Phase 2 Clomipramine
31 Phase Ⅰ/Ⅱ Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 After Oral Administration in Premature Ejaculation Patients Completed NCT01419470 Phase 1, Phase 2 dapoxetine
32 A Randomized, Double-blind, Placebo-controlled, Two-session Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an 16448 in Healthy Males With Premature Ejaculation. Completed NCT00537459 Phase 2 16448
33 An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation Completed NCT02232425 Phase 2 IX-01;Placebo
34 A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation. Completed NCT00370981 Phase 2 pagoclone
35 Effectiveness and Tolerability of Lidocaine 5% Spray in Treatment of Lifelong Premature Ejaculation Patients. A Randomized Single-blind Placebo-controlled Clinical Trial. Completed NCT04062357 Phase 2 Lidocaine 5% spray
36 A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE) Completed NCT03055806 Phase 2 IX-01 400 mg;Placebo;IX-01 800 mg;IX-01 1200 mg
37 A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation Active, not recruiting NCT03578783 Phase 2 Placebo;PSD502
38 An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation Terminated NCT01917006 Phase 2 OnabotulinumtoxinA;Normal Saline
39 A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation Completed NCT00861484 Phase 1 GSK958108;Placebo
40 A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK958108 in Healthy Male Subjects Completed NCT00664365 Phase 1 GSK958108;Placebo
41 A Phase I, Single-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Pharmacokinetic and Safety Study to Evaluate Systemic Exposure and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites 2,6 DiMethylAlanine (2, 6, DMA) and O-Toluidine; and the Safety and Tolerability of PSD502 in Female Healthy Volunteer Subjects Following Daily Application to the Vagina and Cervix for Seven Days With Three Different Doses of PSD502 or Placebo Completed NCT01183208 Phase 1 Intervention A;Intervention B;Intervention C;Intervention D;Intervention E
42 A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Study to Evaluate Systemic and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites, 2,6-Dimethylaniline (2,6-DMA) and O-Toluidine, in Female Healthy Volunteer Subjects Following Daily Application of 60 mg PSD502 or Placebo to the Vagina and Cervix for 7 Days Completed NCT01184105 Phase 1 Intervention A;Intervention B
43 A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects Completed NCT00549211 Phase 1 GSK557296
44 A Two-part, Open-label, Cross-over Study to Assess the Pharmacokinetics of GSK221149 Following Single Oral Doses of Various Modified Release Formulations and a Solution in Healthy Adult Subjects Terminated NCT00449709 Phase 1 GSK221149
45 Investigation of the Changes of Brain Structure and Function in Premature Ejaculation Patients and the Effects of Dapoxetine on Central Neural Activity in Premature Ejaculation Patients Unknown status NCT03583112 Dapoxetine Hydrochloride Tablet;Placebo Tablet
46 Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study Unknown status NCT00656552 Early Phase 1 Escitalopram
47 Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: a 2-year Prospective Observational Study Unknown status NCT03018743 Dapoxetine
48 Safety & Feasibility of Functional Electrical Stimulation for The Treatment of Premature Ejaculation Unknown status NCT03177226
49 Identification Des Bases moléculaires de l'éjaculation prématurée Primaire Unknown status NCT02109302
50 Prevalence of Reproductive Health Problems and Their Social, Psychological and Physical Association Among Men in Floating Population: a Large-Scale Cross-Sectional Study in Dongguan City Unknown status NCT01901029

Search NIH Clinical Center for Premature Ejaculation

Cochrane evidence based reviews: premature ejaculation

Genetic Tests for Premature Ejaculation

Anatomical Context for Premature Ejaculation

MalaCards organs/tissues related to Premature Ejaculation:

40
Cervix, Prostate, Brain, Spinal Cord, Skin, Testis, Pituitary

Publications for Premature Ejaculation

Articles related to Premature Ejaculation:

(show top 50) (show all 1786)
# Title Authors PMID Year
1
Application of micronised acellular dermal matrix for primary premature ejaculation: A preliminary study. 61
33586147 2021
2
Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 61
33226665 2021
3
Validity of Erectile Function Assessment Questionnaires in Premature Ejaculation Patients: A Comparative Study Between the Abridged Forms of the International Index of Erectile Function and Proposal for Optimal Cutoff Redefinition. 61
33384239 2021
4
The relationship between premature ejaculation and the timing of pre-adult circumcision. 61
33709439 2021
5
A Study of Differences in Penile Dorsal Nerve Somatosensory Evoked Potential Testing Among Healthy Controls and Patients With Primary and Secondary Premature Ejaculation. 61
33744179 2021
6
Graph theory analysis reveals premature ejaculation is a brain disorder with altered structural connectivity and depressive symptom: A DTI-based connectome study. 61
33217076 2021
7
Premature Ejaculation patients and their partners: arriving at a clinical profile for a real optimization of the treatment. 61
33754608 2021
8
Selective serotonin re-uptake inhibitors for premature ejaculation in adult men. 61
33745183 2021
9
Spectral analysis of severely overlapping spectra based on newly developed mathematical filtration techniques and ratio spectra manipulations: An application to the concurrent determination of dapoxetine and sildenafil in combined dosage form. 61
33799188 2021
10
Optimization of taste-masked dapoxetine oral thin films using factorial design: in vitro and in vivo evaluation. 61
33663316 2021
11
Erectile Dysfunction in Young Men: Testosterone, Androgenic Polymorphisms, and Comorbidity With Premature Ejaculation Symptoms. 61
33243692 2021
12
Abnormal Thalamic Metabolism in Patients With Lifelong Premature Ejaculation. 61
33358559 2021
13
Changes in the Amplitude of Low-Frequency Fluctuation in Patients With Lifelong Premature Ejaculation by Resting-State Functional MRI. 61
33485114 2021
14
Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity. 61
33442049 2021
15
Safety and efficacy of "on-demand" tramadol in patients with premature ejaculation: an updated meta-analysis. 61
33566469 2021
16
Rs9303628 and rs2054847 of SLC6A4 are protective factors for the onset of lifelong premature ejaculation among the Chinese population. 61
32964515 2021
17
Safety and efficacy of traditional Chinese medicine, Qiaoshao formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men. 61
33236403 2021
18
New approach to patients with premature ejaculation: Do social cognition and attachment profiles play a role in premature ejaculation? 61
33142351 2021
19
Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis. 61
33291044 2021
20
Risk factors of premature ejaculation and its influence on sexual function of spouse. 61
33596817 2021
21
A Preliminary Report on Quality of Life and Sexual Function in Brain Tumor Patients. 61
33563548 2021
22
The influence of prostatic calculi on lower urinary tract symptoms and sexual dysfunction: a narrative review. 61
33718093 2021
23
Study on the relationship between sex hormone changes and erectile dysfunction in patients with chronic prostatitis/chronic pelvic pain syndrome. 61
33353356 2021
24
An Online Questionnaire Survey on the Sexual Life and Sexual Function of Chinese Adult Men During the Coronavirus Disease 2019 Epidemic. 61
33429246 2021
25
Pharmacokinetics and Safety of Dapoxetine Hydrochloride in Healthy Chinese Men: Impact of Dose and High-Fat Meal. 61
33528113 2021
26
The Association Between Female Sexual Dysfunction and Sexual Dysfunction in the Male Partner: A Systematic Review and Meta-Analysis. 61
33303390 2021
27
"The Overactive Pelvic Floor (OPF) and Sexual Dysfunction" Part 1: Pathophysiology of OPF and Its Impact on the Sexual Response. 61
32238325 2021
28
A Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of a Single Oral Dose of 5-HT1A Antagonist GSK958108 on Ejaculation Latency Time in Male Patients Suffering From Premature Ejaculation. 61
33223426 2021
29
Significant relationship between parameters measured by transrectal color Doppler ultrasound and sexual dysfunction in patients with BPH 12 months after TURP. 61
33435935 2021
30
Modafinil Induced Spontaneous Ejaculation Without Orgasm: A Case Report. 61
33252371 2021
31
Sexual relationship, self-esteem, dysfunction, and sexual satisfaction in treatment naïve men with heroin dependence. 61
33441051 2021
32
Spermatorrhea in a Chinese patient with temporal lobe epilepsy: a case report. 61
33445995 2021
33
Premature ejaculation - current concepts in the management: A narrative review. 61
33553999 2021
34
A bibliometric analysis of international publication trends in premature ejaculation research (2008-2018). 61
31896831 2021
35
Temperament-Character Traits and Attitudes Toward Premature Ejaculation in 4 Types of Premature Ejaculation. 61
33339761 2021
36
Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial. 61
31896832 2021
37
Safety and Effectiveness of Dapoxetine On Demand in Chinese Men With Premature Ejaculation: Results of a Multicenter, Prospective, Open-Label Phase IV Study. 61
33529810 2021
38
Aberrant default mode network and auditory network underlying the sympathetic skin response of the penis (PSSR) of patients with premature ejaculation: A resting-state fMRI study. 61
32996293 2021
39
Premature ejaculation in OSAS: Does it improve with CPAP treatment? 61
33497012 2021
40
Upregulated expression of NMDA receptor in the paraventricular nucleus shortens ejaculation latency in rats with experimental autoimmune prostatitis. 61
32749055 2021
41
Brain Functional Biomarkers Distinguishing Premature Ejaculation From Anejaculation by ALFF: A Resting-State fMRI Study. 61
33023837 2020
42
An Internally Validated Nomogram for Predicting the Likelihood of Improvement of Clinical Global Impression in Patients With Lifelong Premature Ejaculation Treated With Dapoxetine. 61
33191185 2020
43
Metacognitions in heterosexual, bisexual, and homosexual men: with or without premature ejaculation and erectile dysfunction. 61
33334382 2020
44
Relationship between atherogenic indices and acquired premature ejaculation. 61
33289173 2020
45
Construction and internal validation of a prediction nomogram for acquired premature ejaculation (APE) in PE patients. 61
33289965 2020
46
Psychosocial stress, somatoform dissociative symptoms and free testosterone in premature ejaculation. 61
32990998 2020
47
Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. 61
32892379 2020
48
Global perspectives on the three criteria for premature ejaculation: An observational study of ejaculatory latency, ejaculatory control and bother/distress. 61
32876352 2020
49
The effect of plasma melatonin levels in the treatment of lifelong premature ejaculation with selective serotonin reuptake inhibitors. 61
32816318 2020
50
Comparison of the safety and efficacy of the on-demand use of sertraline, dapoxetine, and daily use of sertraline in the treatment of patients with lifelong premature ejaculation: A prospective randomised study. 61
33113277 2020

Variations for Premature Ejaculation

Expression for Premature Ejaculation

Search GEO for disease gene expression data for Premature Ejaculation.

Pathways for Premature Ejaculation

GO Terms for Premature Ejaculation

Cellular components related to Premature Ejaculation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.56 HTR2C HTR1B HTR1A COMT
2 integral component of presynaptic membrane GO:0099056 9.33 SLC6A4 SLC6A3 HTR1B
3 G protein-coupled serotonin receptor complex GO:0098666 8.96 HTR2C HTR1B
4 serotonergic synapse GO:0099154 8.62 SLC6A4 HTR1B

Biological processes related to Premature Ejaculation according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 PDE5A OXT LEP HTR2C HTR1B HTR1A
2 response to drug GO:0042493 9.84 SLC6A4 SLC6A3 HTR2C COMT
3 response to organic cyclic compound GO:0014070 9.76 SLC6A3 OXT COMT
4 response to ethanol GO:0045471 9.75 SLC6A3 LEP HTR1B
5 female pregnancy GO:0007565 9.72 OXT LEP COMT
6 regulation of sensory perception of pain GO:0051930 9.61 OXT COMT
7 feeding behavior GO:0007631 9.61 HTR2C HTR1B
8 behavioral fear response GO:0001662 9.6 HTR2C HTR1A
9 eating behavior GO:0042755 9.59 OXT LEP
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.58 HTR2C HTR1B HTR1A
11 neurotransmitter biosynthetic process GO:0042136 9.57 SLC6A4 SLC6A3
12 regulation of behavior GO:0050795 9.52 HTR1B HTR1A
13 dopamine catabolic process GO:0042420 9.51 SLC6A3 COMT
14 response to cocaine GO:0042220 9.5 SLC6A3 OXT HTR1B
15 regulation of dopamine metabolic process GO:0042053 9.49 SLC6A3 HTR1A
16 monoamine transport GO:0015844 9.48 SLC6A4 SLC6A3
17 drinking behavior GO:0042756 9.46 OXT HTR1B
18 response to estradiol GO:0032355 9.46 SLC6A4 OXT LEP CYP19A1
19 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.43 HTR1B HTR1A
20 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.43 HTR2C HTR1B HTR1A
21 sperm ejaculation GO:0042713 9.37 SLC6A4 OXT
22 vasoconstriction GO:0042310 9.13 SLC6A4 HTR1B HTR1A
23 behavior GO:0007610 8.8 HTR2C HTR1B HTR1A

Molecular functions related to Premature Ejaculation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.37 SLC6A3 HTR1B
2 neurotransmitter receptor activity GO:0030594 9.33 HTR2C HTR1B HTR1A
3 neurotransmitter transporter activity GO:0005326 9.32 SLC6A4 SLC6A3
4 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A4 SLC6A3
5 G protein-coupled serotonin receptor activity GO:0004993 9.13 HTR2C HTR1B HTR1A
6 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR1B HTR1A

Sources for Premature Ejaculation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....